Skip to main content

Analgesic drug development: time to break the mould

Success in the introduction of novel, effective and safe analgesics has been notably limited over the past ten years even though existing treatments have low responder rates and a high side effect burden. The pipeline of compounds acting on novel targets is very restricted and there have been many disappointments with drugs that appeared promising in preclinical studies, failing repeatedly in clinical trials. We have to recognize that something is fundamentally wrong with the industry standard approach to the selection of targets, identification of hits, validation of leads and proof of concept clinical studies. A radically alternative strategy is required, one that is driven by the patient and focused on disease phenotype. I will discuss what such an approach may look like and how it may contribute to new therapeutics.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Clifford Woolf.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Woolf, C. Analgesic drug development: time to break the mould. J Headache Pain 14, I2 (2013). https://doi.org/10.1186/1129-2377-14-S1-I2

Download citation

Keywords

  • Public Health
  • Clinical Trial
  • Internal Medicine
  • Clinical Study
  • Drug Development